OTS - Debiopharm encourages breakthrough cancer research in Japan through its competitive JCA Mauvernay Award
2021. October 04. 09:42
Lausanne, Switzerland, 4 October, 2021 (APA/OTS) - Debiopharm
(www.debiopharm.com), a Swiss-based global biopharmaceutical
company, today announced the two winners of the 17th annual JCA
Mauvernay Award for breakthrough Japanese oncology research
projects in 2 categories: Innovative and/or Disruptive Research -
Dr. Shumpei Ishikawa and Translational Research - Dr. Hiromichi
Ebi. The winners were honored with trophies and a monetary prize
during the hybrid (virtual/live) meeting of the 80th Annual Meeting
of the Japanese Cancer Association (JCA) on Saturday, October 2nd
in Yokohama, Japan by Prof. Hideyuki Saya President of the JCA and
Dr. Takato Noumi, Debiopharm's representative in Japan along with
Thierry Mauvernay, President of Debiopharm, Bertrand Ducrey CEO of
Debiopharm who joined virtually.
"Japan and Switzerland share several common values such as
commitment to excellence and professional diligence. That's one of
the reasons why I believe Japanese research continues to excel and
surpass our expectations," expressed Thierry Mauvernay, president
of Debiopharm. "It is our honor to award these two new JCA
Mauvernay Award winners and realize what their early research could
mean for patients in the future through further development."
"We were impressed with the potential implications of
Dr.Ishikawa and Dr. Ebi in different cancer types. Cancer remains
the leading cause of death worldwide so it deserves the deep
exploration by great minds in order to come closer to a cure.
Japanese cancer researchers continue to capture the attention of
the international community as seen in several of the past Nobel
Peace Prizes in Medicine. So, we are very pleased to continue to
this important award and hope to spark further collaboration,"
explained Bertrand Ducrey, CEO of Debiopharm.
Dr. Shumpei Ishikawa's disruptive research at the University of
Toyko, is offering new insights into an aggressive form of gastric
cancer, diffuse-type gastric carcinoma (DGC), by exploring the
genomic characterization the cancer's life cycle. His comprehensive
characterization of DGC includes the identification of genes that
drive the transformation of cells to cancer cells (oncogenes), the
molecular and cellular dissection of the tumor microenvironment and
the environmental factors contributing to the disease. This
holistic approach has led to several influential discoveries that
have been published in top-ranking scientific journals.
Dr. Hiromichi Ebi's translational research at the Aichi Cancer
Center Research Institute is examining the development of targeted
therapies against tumor with aberrant MAPK signaling. His work is
focusing on the elucidation of the molecular mechanisms underlying
the differential clinical activities of drugs targeting mutated
oncogenes depending on the cancerous tissue and the tumor
microenvironment.
The JCA-Mauvernay Award
Since 2005, the Japanese Cancer Association (JCA) and
Debiopharm Group have co-organized the 'JCA-Mauvernay Award'. This
prize illustrates the curiosity that drives researchers as well as
the scientific cooperation between Japan and Switzerland. It aims
at recognizing outstanding achievements in the field of oncology
amongst Japanese researchers, in both the fundamental and the
clinical aspects. The award has a total value of CHF 25'000.
Debiopharm's commitment to patients
Debiopharm develops innovative therapies that target high unmet
medical needs in oncology and infectious diseases. Bridging the gap
between disruptive discovery products and real-world patient reach,
we identify high-potential compounds and technologies for
in-licensing, clinically demonstrate their safety and efficacy and
then select large pharmaceutical commercialization partners to
maximize patient access globally.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Haughton-Bonine
Communication Manager
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.